Signal transducer and activators of transcription 3 regulates cryptotanshinone-induced apoptosis in human mucoepidermoid carcinoma cells

Hyun-Ju Yu*, Chul Park1,*, Sun-Ju Kim2, Nam-Pyo Cho, Sung-Dae Cho

Departments of Oral Pathology and Cancer Biology, School of Dentistry, and Institute of Oral Bioscience, 1Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chonbuk National University, Jeonju, 561-756, 2Department of Dental Hygiene, Division of Health Sciences, Cheongju University, Cheongju, 360-764, South Korea

Submitted: 23-01-2014 Revised: 18-04-2014 Published: 30-08-2014

ABSTRACT
Background: Cryptotanshinone (CT) is a biologically active compound from the root of Salvia miltiorrhiza that has been reported to induce apoptosis in various cancer cell lines; but, it has not yet been fully explored in human mucoepidermoid carcinoma (MEC). Objective: Here, we demonstrated the apoptotic effects and its related mechanism in MC-3 and YD-15 human MEC cell lines. Materials and Methods: The effects of CT on apoptotic activity were evaluated by cell proliferation assay, Western blotting, 4′-6-diamidino-2-phenylindole staining, reverse transcription-polymerase chain reaction, and luciferase assay. Results: Our data show that CT treatment of MC-3 cells results in anti-proliferative and apoptotic activities in MC-3 and it is accompanied by a decrease in phosphorylation and dimerization of signal transducer and activators of transcription 3 (STAT3). CT decreased the expression levels of myeloid cell leukemia-1 (Mcl-1) and surviving, whereas Bcl-xL expression was not changed. CT clearly regulates survivin protein at a transcriptional level and alters Mcl-1 through proteasome-dependent protein degradation. In addition, CT-induced apoptotic cell death in YD-15, another human MEC cell line, was associated with the inhibition of STAT3 phosphorylation. Conclusion: These data suggest that CT could be a good apoptotic inducer through modification of STAT3 signaling in human MEC cell lines.

Key words: Apoptosis, cryptotanshinone, myeloid cell leukemia-1, mucoepidermoid carcinoma, signal transducer and activator of transcription 3, survivin

INTRODUCTION
Signal transducer and activator of transcription 3 (STAT3) belongs to the STAT family of proteins, which are latent cytoplasmic transcription factors that convey signals from the cell surface to the nucleus through cytokines and growth factors.[1] STAT3 has an important role in basic processes including apoptosis, development, differentiation, and proliferation.[2] The activation of STAT3 signaling is initiated by phosphorylation and phosphorylated STAT3 then dimerizes to translocate into the nucleus during normal biological conditions. During maintenance of cell homeostasis, STAT3 activation is rapid and transient. However, constitutive activation of STAT3 is associated with many human cancers.[3,4] Previously, Grandis et al.[5] have reported that oral cancer also exhibits constitutive activation of STAT3 signaling suggesting that STAT3 signaling can be a good molecule for oral cancer including mucoepidermoid carcinoma (MEC).

Cryptotanshinone (CT), one of the major tanshinones isolated from Salvia miltiorrhiza Bunge (Danshen) has been used in Chinese medicine for the treatment of various diseases including coronary artery disease, hyperlipidemia, acute ischemic stroke, and Alzheimer’s disease.[6-8] CT also has the unique biological activity of inhibiting the phosphorylation of STAT3, and thus it has been categorized as a STAT3 inhibitor. Recently, several groups reported that CT arrests cell cycle and induces apoptosis in several cancer cell lines.[9-11] However, there have not been any reports on the possible anticancer activities of CT in human MEC cell lines.

In this study, we investigated the apoptotic effects of CT and the mechanism by which it regulates STAT3 in two human MEC cell lines (MC-3 and YD-15). Our results
provide that CT can inhibit STAT3 signaling in order to exert apoptotic activity through blocking phosphorylation and dimerization of STAT3.

**MATERIALS AND METHODS**

**Chemicals and antibodies**
Cryptotanshinone [Figure 1a], 4'-6-diamidino-2-phenylindole (DAPI) and cycloheximide (CHX) were purchased from Sigma-Aldrich Chemical Co., (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO). The actin antibody and MG-132 were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibodies for cleaved poly ADP ribose polymerase (PARP), cleaved caspase-3, p-STAT3, STAT3, survivin, myeloid cell leukemia-1 (Mcl-1) and Bcl-xL were purchased from Cell Signaling Technology Inc. (Charlottesville, VA, USA).

**Cell culture and chemical treatment**
MC-3 cells were kindly provided by Dr. Wu Junzheng from Forth Military Medical University (Xi’an, China) and YD-15 cells were obtained from Yonsei University (Seoul, Korea). MC-3 cells were grown in DMEM, and YD-15 cells were grown in RPMI-1640; both types of media were supplemented with 10% fetal bovine serum in CO₂ incubator. An equal number of cells were seeded. When cells reached at 50-60% confluence, they were treated with DMSO or various concentrations of CT.

**Cell viability assay**
The cell lines were treated with different concentrations of CT (2, 4, or 8 µM for MC-3; 5, 10, or 15 µM for YD-15) for 24 h. The number of surviving cells was counted using a hemacytometer with 0.4% of trypan blue. Each experiment was performed in triplicate, and the results were expressed as the percentage of surviving cells compared to DMSO treatment group.

**Western blotting**
Cell lysates were extracted with lysis buffer and quantified with a DC Protein Assay kit (Bio-RAD, Hercules, CA, USA). Protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membrane (Bio-RAD). Membranes were blocked with 5% skim milk in TBST buffer at room temperature (RT) for 1 ~ 1.5 h, washed with TBST, and maintained overnight at 4°C with designated primary antibodies. Subsequently, membranes were incubated with a horseradish peroxidase-conjugated secondary antibody at RT for 2 h. Antibody-bound proteins were detected using an ECL Western Blotting Luminol Reagent (Santa Cruz Biotechnology Inc.).

**4'-6-diamidino-2-phenylindole staining**
Evaluation of fragmentation and condensation in the nuclei of apoptotic cells was performed using DAPI. After CT treatment, cells were harvested by trypsinization and fixed in 100% methanol for 10 min at RT. The cells were resuspended in phosphate-buffered saline, deposited on poly-L-lysine coated slides, and stained with a DAPI solution. Nuclear condensation

![Figure 1](image_url)  
*Figure 1:* The effect of cryptotanshinone (CT) on cell viability and apoptosis in MC-3 cells. (a) Chemical structure of CT. MC-3 cells were treated with 2, 4, or 8 µM of CT for 24 h. Cell viability was determined using a trypan blue exclusion assay. (b) The apoptotic effect of CT was determined by Western blot analysis using the antibodies against cleaved poly ADP ribose polymerase and cleaved caspase 3 (c) and 4'-6-diamidino-2-phenylindole staining. (d) Results are expressed as means ± standard deviation for triplicate experiments and significance (P < 0.05) compared with dimethyl sulfoxide-treated cells is given (*)
and fragmentation were detected under a fluorescence microscope.

**Cross-linking**
For STAT3 dimerization, the cells were suspended in conjugation buffer with 10 mM EDTA. The cell lysates were incubated with 0.2 mM bismaleimide (Thermo scientific, Rockford, IL, USA) at RT for 1 h, and then extracted with lysis buffer for Western blotting.

**Reverse transcription-polymerase chain reaction**
After chemical treatment, RNA was isolated using an easy-blue total RNA Extraction kit (iNtRON, Seongnam, Korea). RNA was used to synthesize cDNA using a RT System (Promega, Madison, WI, USA). The following primer sequences were used; survivin: 5'-ATG GGC GAG GCT GCC TTC ATC-3' (S), 5'-AGG GGC CAC TTT CTT CGC AGT T-3' (AS); Mcl-1 5'-TGC TGG AGT TGG TCG GGG AA-3' (S), 5'-TCG TAA GGT CTC CAG CGC CT-3' (AS); β-actin 5'-GTG GGG CGC CCC AGG GTC GGC TTC ATC-3' (S), 5'-ACG GCG CAC TTT CTT GGC ATG AGG AGC ACT T-3' (AS). Polymerase chain reaction (PCR) conditions were followed: 28 cycles: 60 s at 95°C, 60 s at 60°C and 90 s at 72°C for survivin and Mcl-1, and 25 cycles: 60 s at 95°C, 60 s at 60°C and 90 s at 72°C for β-actin. PCR products were analyzed by 1-2% agarose gel electrophoresis and visualized by ethidium bromide staining.

**Dual-luciferase assay**
Promoter activity was evaluated using a Dual-Luciferase Reporter Assay (Promega) according to the manufacturer’s instructions. In brief, cells were seeded in 12-well plates and transfected with a human survivin and Mcl-1 luciferase reporter plasmid using Lipofectamine 2000 reagent (Invitrogen) and cultured for 6 h. The culture medium was removed, and cells were treated with CT for 24 h. Cells were lysed by incubation for 15 min with 1× passive lysis buffer and cell debris was removed by centrifugation. The supernatant was assayed for Firefly and Renilla luciferase activities using a Microbeta Trilux 1450 luminescence counter (Perkin Elmer, Turku, Finland).

**Statistical analysis**
Data were assessed for statistical significance using Student’s t-test. A value of $P < 0.05$ compared to the vehicle control was considered to be statistically significant.

**RESULTS**

**Cryptotanshinone decreases cell viability and induces apoptosis in human mucoepidermoid carcinoma MC-3 cells**
To investigate the inhibitory effect of CT on cell growth, MC-3 cells were treated with DMSO or different concentrations of CT (2, 4, and 8 µM) for 24 h. As shown in Figure 1b, treatment with CT for 24 h significantly decreased the viability of MC-3 cells in a concentration-dependent manner. To understand how CT decreases cell viability, the effect of CT on apoptosis was assessed using Western blotting and DAPI staining. We found that CT caused increases in the cleavages of PARP and caspase-3 [Figure 1c]. The distinct features of apoptotic cells, nuclear condensation and fragmentation were also significantly increased in the CT-treated group compared with the DMSO-treated group [Figure 1d]. These results suggest that the inhibition of cell viability by CT is attributed to the induction of apoptotic cell death.

**Cryptotanshinone regulates survivin and myeloid cell leukemia-1 expression through the inactivation of signal transducer and activators of transcription 3 kinase**
Because CT was previously identified as an inhibitor of STAT3,[12] we hypothesized that CT may inactivate STAT3 signaling in MC-3 cells. To test this hypothesis, the effect of CT on STAT3 phosphorylation in MC-3 cells was investigated. The results showed that CT significantly reduced STAT3 phosphorylation [Figure 2a]. STAT3 phosphorylation causes its homo-dimerization and subsequent translocation to the nucleus for binding to specific DNA sequences in the promoters of target genes.[4,13] Therefore, we analyzed the effect of CT on STAT3 dimerization. As shown in Figure 2b, CT clearly decreased the amounts of dimerized STAT3 concentration-dependently. Dimerized STAT3 can regulate the expression of target proteins involved in cell proliferation, survival, and angiogenesis.[14,15] We investigated whether the expression levels of survivin, Mcl-1 and Bel-xL were affected by CT and the results showed that CT suppressed the expression of survivin and Mcl-1 protein, but did not affect Bel-xL protein levels [Figure 2c]. These results suggest that CT has an effect on STAT3 signaling that results in a decrease in survivin and Mcl-1 protein.

**Cryptotanshinone decreases survivin protein at the transcriptional level and alters myeloid cell leukemia-1 protein expression by the posttranslational modification**
To determine how CT regulates survivin and Mcl-1 proteins, we examined the expression levels of survivin and Mcl-1 mRNA and their promoter activities using RT-PCR and dual-luciferase assay in MC-3 cells. The results showed that CT significantly attenuated survivin mRNA and its promoter activity, but Mcl-1 mRNA levels and promoter activity were not altered in MC-3 cells [Figure 3a and b]. The effect of CT on Mcl-1 protein...
Yu, et al. : Cryptotanshione induces apoptosis through STAT3

Figure 2: The effect of cryptotanshinone (CT) on signal transducer and activators of transcription 3 (STAT3) signaling. MC-3 cells were treated with 2, 4, or 8 µM of CT for 24 h. p-STAT3 and STAT3 were analyzed by Western blot analysis. (a) STAT3 dimerization was performed by Western blot analysis after treatment with cross-linker BMH. (b) Survivin, myeloid cell leukemia-1 and Bcl-xL proteins were determined in MC-3 cells treated with CT by Western blot analysis. (c) All data are expressed as means ± standard deviation for triplicate experiments and significance (*P < 0.05) compared with dimethyl sulfoxide-treated cells is indicated (*).

Inhibition of signal transducer and activators of transcription 3 phosphorylation by cryptotanshione induces apoptosis in YD-15 cells

To evaluate whether the modification of STAT3 signaling by CT generally occurred in human MEC cell line during apoptosis, YD-15 cell, another human MEC cell line was used. Figure 4a showed that CT effectively inhibited the viability of YD-15 cells. CT clearly induced caspase-related PARP cleavage [Figure 4b] and increased the number of YD-15 cells displaying nuclear condensation and fragmentation [Figure 4c]. We also found that CT significantly inhibited STAT3 phosphorylation [Figure 4d]. These data suggest that CT also decreases STAT3 phosphorylation in order to induce apoptosis in another MEC cell line. Figure 5 is the summary of the molecular mechanism by which the treatment with CT inhibits the STAT3 signaling pathway to induce apoptosis in MEC cell lines through regulation of survivin and Mcl-1 expression.
Figure 3: The effects of cryptotanshione (CT) on survivin and myeloid cell leukemia-1 (Mcl-1). Survivin and Mcl-1 mRNA levels were confirmed by RT-PCR in MC-3 cells and normalized to β-actin. (a) MC-3 cells were transfected with PGL3 vector control (white bar) or survivin and Mcl-1 promoter construct (black bar), treated with CT, and induction of luciferase activity was determined. (b) The effect of CT on Mcl-1 protein turnover was determined by Western blot analysis in MC-3 cells treated with the protein synthesis inhibitor, cycloheximide (0.4 µg/ml) with/without CT (8 µM) for 24 h. (c) MC-3 cells were pretreated for 1 h with the proteasome inhibitor, MG-132 (40 nM) or dimethyl sulfoxide (DMSO) and CT (8 µM) or DMSO were added for 3 h. Then, Mcl-1 expression was determined by Western blot analysis. (d) All data are expressed as means ± standard deviation for triplicate experiments and significance (P < 0.05) compared with DMSO-treated cells is indicated (*).

Figure 4: The effect of cryptotanshione (CT) on apoptosis and signal transducer and activators of transcription 3 (STAT3) in YD-15 cells. YD-15 cells were treated with 5, 10, or 15 µM of CT for 24 h. Cell proliferation was determined using a trypan blue exclusion assay. (a) The apoptotic effect of CT was determined by Western blot analysis using the antibodies against cleaved poly ADP ribose polymerase and cleaved caspase 3 (b) and 4′,6-diamidino-2-phenylindole staining. (c) p-STAT3 and STAT3 were analyzed by Western blot analysis. (d) Results are expressed as means ± standard deviation for triplicate experiments and significance (P < 0.05) compared with dimethyl sulfoxide-treated cells is indicated (*).
DISCUSSION

The purpose of this study was to demonstrate whether CT could suppress the proliferation of MEC cells by interfering with STAT3 pathways. We have shown that CT has significant growth-inhibitory and apoptotic effect in MC-3 cells. In agreement with our present study, other group also reported that CT treatment induced programmed cell death in various cancer cell lines. These results suggest that CT can be a good inducer of apoptosis in cancer cells.

The STAT protein family includes seven proteins that mediate the transduction of extracellular signals for the transcription of target genes. Among the STATs, STAT3 is closely associated with tumorigenesis. Constitutive activation of STAT3 represents one of the critical events in multistep carcinogenesis. Recently, it was found that the inhibition of STAT3 induces apoptosis in human prostate cancer cell lines implying that STAT3 can be useful for the treatment of various cancer as a potential molecular target. Previously, it was reported that CT is one of the major active components of Danshen as a small-molecule inhibitor of STAT3 transcriptional regulatory activity. In this study, we confirmed that CT treatment inhibited STAT3 phosphorylation, which may be related to CT-induced apoptosis in MEC cell lines.

Signal transducer and activators of transcription 3 phosphorylation and homo-dimerization cause subsequent translocation of STAT3 to the nucleus where it affects the expression of target proteins. Survivin is highly expressed in various types of human cancers, including breast, colon, liver, lung, ovarian, pancreas, prostate, stomach, and hematopoietic malignancies, as well as melanoma. Our previous studies also showed that survivin is a key mediator for MEC cell lines and several compounds blocked survivin during apoptotic cell death. It was recently shown that constitutive activation of STAT3 can modify the expression level of survivin protein in malignant cells suggesting that survivin may be regulated by the STAT3 signaling pathway. Thus, we investigated the effects of CT on survivin and the results showed that CT clearly reduced the expression level of survivin protein at a transcriptional level evidenced by the suppression of mRNA and its promoter activity in response to CT. Several pieces of evidence demonstrate that the abnormal activity of STAT3 promotes tumorigenesis by increasing the expression of anti-apoptotic Bcl-2 family members, such as Bcl-2, Bcl-xL, and Mcl-1. Among them, inhibition of constitutive STAT3 activation in malignant cells can suppress Bcl-xL or Mcl-1 genes. We found that CT decreased Mcl-1 protein levels, but did not alter Bcl-xL levels in MC-3 cells. Interestingly, CT did not affect the expression level of Mcl-1 mRNA or its promoter activity indicating that Mcl-1 may not be regulated by CT at a transcriptional modification. Our previous reports revealed that several compounds such as tolfenamic acid and mithramycin A decreased Mcl-1 protein associated with proteasome-dependent protein degradation. Other group also reported that Mcl-1 protein was rapidly degraded by the proteasome suggesting that it could be modulated by posttranslational modification. Consistent with these findings, treatment with CT accelerated the clearance of Mcl-1 protein after the inhibition of protein synthesis by CHX and the inhibition of the proteasome function by MG-132 partially reversed the down-regulation of Mcl-1 by suggesting that CT does affect the stability of synthesized Mcl-1. The results suggest that CT clearly regulates survivin protein at a transcriptional level and alters Mcl-1 protein through the proteasome-dependent protein degradation.

To ensure that the in vitro activities seen in MC-3 cells are not cell line-specific, we examined the apoptotic effect of CT in YD-15, another human MEC cell line. The result showed that CT also can induce apoptotic cell death accompanied by inhibition of STAT3 phosphorylation in YD-15 cells. This suggests that STAT3 is a general molecular pathway that plays a critical role in CT-induced apoptosis in human MEC cell lines.

In summary, we have confirmed for the 1<sup>st</sup> time that CT is an effective apoptotic inducer through regulation.
of the STAT3 signaling pathway in human MEC cell lines. Therefore, we suggest that CT may be a promising anticancer drug candidate for the treatment of MEC. However, further direction using an animal model is needed before clinical application of CT.

ACKNOWLEDGMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012R1A2A2A01003731 and 2013R1A1A2057882).

REFERENCES

1. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5.
2. Al Zaid Siddique K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18:254-67.
3. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-9.
4. Turkson J, Jove R. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26.
5. Grandsis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998;102:1385-92.
6. Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol 2007;121:9-22.
7. Zhou L, Zuo Z, Chow MS. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005;45:1345-59.
8. Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, et al. Transport of cryptotanshinone, a major active triterpenoid in Acalypha australis L.targeting specificity protein 1 in human oral cancer cells. Head Neck 2013;35:992-8.
9. Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X, et al. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res (Phila) 2010;3:1015-25.
10. Xiang Y, Zhang X, Nix DB, Katoh T, Aoki K, Tiemeyer M, et al. Regulation of protein glycosylation and sorting by the Golgi matrix proteins GRASP55/65. Nat Commun 2013;4:1659.
11. Park IJ, Kim MJ, Park OJ, Choe W, Kang I, Kim SS, et al. Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells. Apoptosis 2012;17:248-57.
12. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 2009;69:193-202.
13. Yu H, Korylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
14. Yu H, Jove R. The STATs of cancer – New molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
15. Bromberg JF, Wrezeszczyńska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
16. Ge Y, Cheng R, Zhou Y, Shen J, Peng L, Xu X, et al. Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Mol Cell Biochem 2012;368:17-25.
17. Li H, Zhang Q, Chu T, Shi HY, Fu HM, Song XR, et al. Growth-inhibitory and apoptosis-inducing effects of tanshinones on hematological malignancy cells and their structure-activity relationship. Anticancer Drugs 2012;23:846-55.
18. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009;15:79-80.
19. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56.
20. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004;60:303-9.
21. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66.
22. Gao LF, Xu DQ, Shao YT, Zhao D, Zhao XJ. Knockdown of STAT3 expression using siRNA inhibits the growth of prostate cancer cell lines. Zhonghua Nan Ke Xue 2005;11:29-33, 37.
23. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73.
24. Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: A promising tumor biomarker. Cancer Lett 2007;249:49-60.
25. Shin JA, Hen G, Park SK, Lee K, Kim HJ, Cho SD, et al. The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells. Oral Dis 2013;20:482-8.
26. Shin JA, Kim JJ, Choi ES, Shim JH, Ryu MH, Kwon KH, et al. In vitro apoptotic effects of methanol extracts of Dianthus Chinensis and Acalypha australis L. targeting specificity protein 1 in human oral cancer cells. Head Neck 2013;35:992-8.
27. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9.
28. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006;12:20-8.
29. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
30. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107:351-62.
31. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-44.
32. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003;9:316-26.
33. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 2007;104:7391-6.

34. Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2007;2:787-98.

35. Choi ES, Shim JH, Jung JY, Kim HJ, Choi KH, Shin JA, et al. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 2011;102:742-8.

36. Choi ES, Jung JY, Lee JS, Park JH, Cho NP, Cho SD. Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Lett 2013;328:65-72.

37. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003;17:1475-86.

38. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 2003;22:7108-22.

39. Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem 2004;279:26915-21.